EGFR and lung carcinoma: By examining pTyr signaling in an unbiased fashion on a global scale, our results confirm the central importance of RAS signaling in lung cancer, and suggest that particularly strong activation of RAS may be a hallmark of cancers that are driven by EGF receptor mutation and are sensitive to EGFR inhibitors (i.e. are “addicted” to EGFR signaling).